Tenecteplase as Alteplase Substitute
Tenecteplase (0.4 mg/kg IV bolus, maximum 40 mg) is the preferred substitute for alteplase when it is unavailable in acute ischemic stroke, particularly in patients with minor neurological impairment and no major intracranial occlusion. 1
Guideline-Based Recommendation
The 2018 AHA/ASA Stroke Guidelines explicitly address this scenario, stating that tenecteplase administered as a 0.4 mg/kg single IV bolus might be considered as an alternative to alteplase (Class IIb, Level of Evidence B-R). 1 This represents the only FDA-approved alternative thrombolytic with guideline support for acute ischemic stroke.
Key Advantages of Tenecteplase
- Single bolus administration (over 5-10 seconds) versus alteplase's 60-minute infusion 1
- Longer half-life and greater fibrin specificity 2, 3
- Faster door-to-needle times in real-world practice 4
- Similar safety profile with comparable symptomatic intracranial hemorrhage rates 5
Clinical Context and Evidence
The largest trial (1,100 patients) showed tenecteplase at 0.4 mg/kg had a safety and efficacy profile similar to alteplase, though it failed to demonstrate superiority. 1 The study population predominantly consisted of patients with minor neurological impairment (median NIHSS score 4) and no major intracranial occlusion. 1
Important limitation: Tenecteplase has not been proven superior or noninferior to alteplase across all stroke populations, but appears similarly safe based on multiple phase II and III trials. 1
What NOT to Use
The guidelines are clear that other IV fibrinolytics should NOT be used outside clinical trials (Class III: No Benefit):
- Streptokinase - No benefit demonstrated, not recommended 1
- Desmoteplase - No benefit demonstrated within 3-9 hours 1
- Other defibrinogenating agents - Unproven benefit 1
Practical Implementation
When alteplase is unavailable:
- Verify eligibility criteria - Use the same time windows and contraindications as alteplase (within 3-4.5 hours)
- Dose tenecteplase at 0.4 mg/kg IV bolus (maximum 40 mg)
- Administer as single bolus over 5-10 seconds
- Proceed with mechanical thrombectomy if indicated - do not delay for clinical response 1
Critical Caveat
Patients eligible for IV thrombolysis should receive it even if mechanical thrombectomy is being considered - this applies to both alteplase and tenecteplase. 1 The logistical advantage of tenecteplase's bolus administration may facilitate faster transfer to thrombectomy-capable centers. 6
Emerging Alternative
Recent 2026 data suggests prourokinase may be another option, showing non-inferiority to alteplase with potential cost advantages 7, but this lacks guideline support and is not yet widely available in most settings.